Creabilis Receives Prestigious Technology Strategy Board Biomedical Catalyst Award
Dr Eliot Forster, CEO of Creabilis, said: "It is satisfying to have won this highly prestigious award and we are grateful to the Technology Strategy Board for their diligence. We firmly believe that CT327 will make a real difference to patients suffering from Atopic Dermatitis. The Biomedical Catalyst funding will enable us to complete this important study bringing CT327 one step closer to all patients suffering from this common and poorly treated disease."
About Creabilis SA
Creabilis is a clinical-stage European biotechnology company creating innovative new drugs to tackle unmet medical needs in dermatology and inflammatory diseases. Bringing together world-class drug development capabilities and a rich scientific heritage, Creabilis is uniquely positioned to transform the treatment of its target diseases.
Creabilis' lead product is CT327, a novel, topically-applied TrkA kinase inhibitor developed using the Company's Low Systemic Exposure (LSE) technology. CT327 is currently in Phase II clinical trials in Psoriasis and a Phase IIb study in Atopic Dermatitis will begin in 2013. CT340 is a potent kinase inhibitor under development for the treatment of conditions in which TrkA, p38, JAK3 kinase inhibition is indicated, including inflammatory arthritis and pain. Earlier-stage projects include a number of highly promising LSE-based candidates for wider indications requiring topical therapy.Creabilis is backed by some of Europe's most highly respected life sciences investors including Sofinnova Partners, Neomed and Abbott Biotech Ventures, Inc. For more information, please visit: http://www.creabilis-sa.com About the Technology Strategy Board The Technology Strategy Board is the UK's innovation agency. Its goal is to accelerate economic growth by stimulating and supporting business-led innovation. Sponsored by the Department for Business, Innovation and Skills (BIS), the Technology Strategy Board brings together business, research and the public sector, supporting and accelerating the development of innovative products and services to meet market needs, tackle major societal challenges and help build the future economy. For more information please visit http://www.innovateuk.org. About the Biomedical Catalyst
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts